Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanogen Issued Patent

Abstract:
Method described allows hybridization of DNA to be detected while conducting PCR

Nanogen Issued Patent for Method of Monitoring PCR Using Fluorescent Energy Transfer

Nanogen

San Diego, CA | July 07, 2005

Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today it was issued Patent No. 6,911,310, "Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system" by the U.S. Patent and Trademark Office. The '310 patent relates to a method of monitoring polymerase chain reaction (PCR) amplification of nucleic acid (DNA or RNA) using fluorescent resonant energy transfer (FRET), which is an essential part of molecular diagnostics. Marking the 131st patent to issue to Nanogen, it is closely related to the patents previously issued that describe nanofabrication and self-assembly of photonic molecular structures.

The method described in the '310 patent allows hybridization of DNA to be detected while conducting PCR. The process begins with oligonucleotides that are labeled with donor or acceptor fluorophores, each fluorophore illuminating at a unique wavelength of light upon excitation. When a donor fluorophore is excited, it absorbs energy and transfers it to an acceptor fluorophore that is located within a specific distance to the donor. Energy transfer is permitted in this way when two oligonucleotides, one labeled with a donor fluorophore and one with an acceptor fluorophore, are hybridized to a target nucleic acid. Hybridization places the donor and acceptor fluorophores within transfer distance from each other. The transfer of energy brings a shift in the emitted wavelength that can be detected as a change in the color of the light. In the absence of a target, no energy transfer or change in color occurs. By measuring the emission wavelength that results from the energy transfer to the acceptor fluorophore, the presence of the target nucleic acid can be detected.

"Nanogen's research in nanotechnology and fluorescent energy transfer is the continuation of many years of work," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Our growing intellectual property estate includes valuable technologies involving methods of fluorescent energy transfer that can be used for the creation of useful DNA diagnostic assay systems."


####

About Nanogen:
Nanogen's advanced diagnostics provide researchers, clinicians, physicians and patients worldwide with improved methods and tests that can predict, diagnose and ultimately help treat disease. Nanogen's products include real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular diagnostic applications and its line of rapid point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries.

For more information, please visit www.nanogen.com

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.



Contacts:
Robert Saltmarsh
Chief Financial Officer of Nanogen, Inc.
+1-858-410-4600
rsaltmarsh@nanogen.com

Media & Investor Relations Contact:
Pam Lord
Atkins + Associates
+1-858-527-3494
plord@irpr.com

Copyright © Nanogen

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE